BriaCell Announces Presentation of Clinical and Scientific Findings at AACR Annual Meeting
June 22 2020 - 8:01AM
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”)
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, is announcing the results of clinical studies with its lead
product candidate, Bria-IMT™, summarized in a poster session during
AACR Annual Meeting 2020, Virtual Meeting II, a virtual event held
June 22-24, 2020.
The poster describes clinical and
pharmacodynamic responses to Bria-IMT™ regimens in patients with
advanced breast cancer from two phase I/IIa trials, one with 23
evaluable patients treated with Bria-IMT™ as monotherapy and the
other with 11 evaluable patients treated with Bria-IMT™ in
combination with pembrolizumab (KEYTRUDA®; manufactured by Merck
& Co., Inc.). In essence, the poster demonstrates that patients
with tumor regression (i.e., a decrease in the size of a tumor)
tended to have certain biologic characteristics, including well or
moderately differentiated tumors. The patient data summarized and
discussed belong to previously-disclosed patients (i.e., no
incremental numbers enrolled).
The abstracts published in advance of the AACR
meeting were made available for viewing through the AACR website.
The poster is posted
on https://briacell.com/novel-technology/scientific-publications/.
The details of BriaCell’s AACR poster are as follows:
Presentation Title: Clinical
and pharmacodynamic responses to a modified whole tumor cell
immunotherapy in patients with advanced breast cancer from two
phase I/IIa trialsSession Date: Monday, June
22, 2020Session Time: 9am ET
Summarized Data:
Monotherapy Study
- The patients were heavily pre-treated having failed an average
of 5 prior regimens.
- Of 23 patients studied, 1 had “well”, and 5 had “moderately”
differentiated tumors with the rest poorly differentiated.
- One patient in the monotherapy study with a “poorly”
differentiated tumor showed tumor regression, whereas 2 patients
with “well” or “moderately” differentiated tumors had tumor
regressions.
- The responders have a higher tendency to develop T cell
proliferative responses per se compared to non responders.
Combination Study
- The patients were heavily pre-treated having failed an average
of 4 prior regimens.
- Of 11 patients in the study with KEYTRUDA®, 3 had “moderately”
differentiated tumors.
- Tumor regression was observed in 2 patients. Both patients had
“moderately” differentiated tumors, similar to the tumor from which
Bria-IMT™ was derived.
Both Studies
- Patients with “well” or “moderately” differentiated tumors were
analyzed separately. This included 6 patients from the monotherapy
study (5 able to develop an immune response) and 3 from the
combination therapy study (all able to develop an immune response).
One patient started her treatment on monotherapy study and
continued on the combination therapy study.
- Patients had multiple prior treatments with median of 7 prior
treatment regimens.
- Patients with “well” or “moderately” differentiated tumors were
more likely to show disease control (86% response rate in immune
responders).
In conclusion, the data indicates that the
Bria-IMT™ regimen with or without KEYTRUDA® appears to be able to
induce an effective immune response and tumor regression in
advanced breast cancer patients. Patients with “well” or
“moderately” differentiated tumors were more likely to respond with
tumor regression and disease control. A more robust immune response
appeared to have occurred in patients who responded to treatment
with tumor regression compared to those who did not.
About AACR
The AACR was founded in Washington, D.C., May 7,
1907, by a group of 11 physicians and scientists intending “to
further the investigation and spread the knowledge of cancer.” To
prevent and cure cancer using research, education, communication,
collaboration, funding and advocacy has been the mission of AACR.
With its programs and services, AACR advances research in cancer
and related biomedical science by facilitating exchange of
knowledge and innovations among scientists and clinicians dedicated
to the fight against cancer, providing education and training in
oncology treatment and advancing cancer etiology, prevention, early
detection, diagnosis and treatment worldwide.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to known
and unknown risks relevant to the Company in particular and to the
biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but
are not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics
Corp.:William V. Williams, MDPresident & CEOPhone:
1-888-485-6340
BriaCell Therapeutics
Corp.:Farrah DeanManager, Corporate DevelopmentEmail:
farrah@BriaCell.com Phone: 1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024